Collective Health

collectivehealth.com →

-39%

est. 2Y upside i

HealthcareSeries D+

Health benefits administration platform for self-funded employers

Rank

#3611

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Medium

Collective Health operates in a growing HealthTech market with $143M revenue, but faces high incumbent and competitive threats from established players like Aetna and well-funded rivals such as Accolade.

Last updated: March 10, 2026

Bull (15%)+100%

Collective Health successfully navigates regulatory complexities and expands its market share through strategic partnerships (e.g., Providence Health Plan, Noom) and product innovation (e.g., Guide Plans, AI integration), driving revenue to over $280M by 2028 and justifying a $3.0B valuation. This would allow common shareholders to see strong returns after clearing the preference stack.

Base (50%)+20%

Collective Health maintains its position in the self-funded employer market, growing steadily at ~12% YoY, reaching ~$179M revenue by 2028. However, intense competition and incumbent threats limit significant multiple expansion, leading to a modest $1.8B valuation. Common shareholders would see a moderate return after preferences.

Bear (35%)-40%

Increased regulatory scrutiny (e.g., 2025 Comprehensive Reform Act) and aggressive competition from incumbents (e.g., Aetna, UnitedHealth) or well-funded rivals (e.g., Accolade, Transcarent) erode market share and pricing power. This leads to slower growth, a down round, or an acquisition at $0.9B, resulting in significant losses for common stock holders due to the $719M liquidation preference.

Est. time to liquidity~2.5 years

Adjusted for competitive dynamics: -9% (raw: -39%, adjustment: -20%)

Preference Stack Risk

severe

Funding Intensity

48%

Investors hold $719M in liquidation preferences ahead of common stock, representing 47.9% of the current $1.5B valuation. In an exit at or below this valuation, common stock holders may receive little to nothing.

Dilution Risk

high

As a Series F company, further funding rounds are possible, which could dilute existing common stock holders, especially given the significant prior funding and the need to clear a substantial preference stack.

Secondary Liquidity

limited

Secondary markets exist (e.g., UpMarket, Forge, EquityZen, Hiive, Nasdaq Private Market) but are typically restricted to accredited investors and may be subject to company approval or lock-up periods for employees.

Questions to Ask at the Interview

Strategic questions based on Collective Health's data — designed to show you've done your homework.

1
“How is Collective Health thinking about defending its market position and pricing power against dominant incumbents like Aetna and well-funded competitors such as Accolade and Transcarent?”
2
“Given the Series F funding and current revenue, what is the company's realistic path to profitability and a liquidity event (IPO or acquisition) for employees within the next 2-3 years?”
3
“With a significant liquidation preference stack, what mechanisms or strategies are in place to ensure meaningful returns for common stock holders in various exit scenarios, and what is the company's stance on secondary liquidity for employees?”

Community

Valuation Sentiment

Our model estimates -39% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.